10.00 Introduction - Dr Ray Munden, Chairman, Joint Pharmaceutical Analysis Group
10.05 Regulatory overview: key analytical issues in global product approval - Dr Prasad Peri, FDA
10.45 Formulators perspective: key analytical issues in expediting product development - Dr Philippe Rogueda, Novartis
11.20 Relationship between in-vitro and in-vivo data - Gary Pitchairn, Pfizer
11.55 Current issues in cascade impaction - Frank Chambers, AZ
12.30 Lunch
13.45 Recent experiences with automation of inhaled product testing - Dave Russell-Graham, Pfizer, and Andy Rice, GSK
14.20 Evaluating the robustness of drug delivery from nasal spray and nebuliser devices using laser diffraction particle sizing
Dr Paul Kippax, Malvern Instruments
14.55 Powder rheology as a tool for predicting formulation performance - Professor Rob Price. University of Bath
15.30 Use of NMR in pMDI development - Dr Dave Martin, AZ
16.05 Closing remarks
16.15 Close